Skip to content
XGenomes logo

XGenomes

XGenomes is a YC Winter 2019 (W19) company. Based in Cambridge, MA, USA. Team of 6.

  • Genomics

About XGenomes

GPAgent's own fund-neutral profile, written from public information. Updated Oct 5, 2026.

Summary

XGenomes builds a DNA sequencing platform that eliminates library preparation, integrates extraction and sequencing into a single instrument, and reads both strands of the double helix concurrently to produce highly accurate, complete genomic data. The system uses super-resolution fluorescence imaging and machine learning to capture single-nucleotide variants, structural variants, haplotype phase, and epigenetic information in one workflow. It targets precision healthcare providers and researchers who currently rely on multi-step sequencing pipelines requiring separate preparation, sequencing, and bioinformatics stages.

Business model

Sequencing offered initially as a service, followed by instrument sales paired with consumables.

Go-to-market

High-value genomics and precision healthcare customers are the initial target, reached first through a sequencing-as-a-service model before transitioning to direct instrument sales.

From the Y Combinator listing

How XGenomes describes itself in Y Combinator's public directory. Original listing (opens in a new tab)

XGenomes is building the sequencing technology of the future.

At XGenomes, we are building a technology comprising novel biochemistry, hardware and algorithms for sequencing DNA. Our product will be streamlined: there is zero library preparation; we sequence directly on unadulterated single molecules of DNA; DNA extraction will be integrated with sequencing; there is no bioinformatics bottleneck. The sequence we produce will be of unprecedented accuracy due to several layers of in-built redundancy including the sequencing both strands of the double-helix concurrently. The sequence we produce will be complete, encompassing: structural as well as single nucleotide variants; long-range haplotype phase; the repetitive "dark matter" of the genome. The cost of goods (consumables) of sequencing will be <$10, which will allow us to price our product at a level that will help grow the market while still achieving >90% margin. We will start by offering access as a service to high value customers, which be followed by a razor and blade model of selling instruments and consumables.

Facts

Industry
Healthcare / Healthcare -> Diagnostics
Location
Cambridge, MA, USA
Team size
6
Status
Active
Stage
Early

Founders (1)

Score every batch against your own thesis

GPAgent's sourcing agent reads every company in a batch, scores each one against your fund's thesis in a private workspace, and lines up the founders worth meeting before Demo Day. You decide who to contact. Your scores, notes, and pipeline never appear on these pages.

How Accelerator intelligence works